Testosterone and Depressive Symptoms: What a 27-Trial Meta-Analysis Found

Testosterone and Depressive Symptoms: What a 27-Trial Meta-Analysis Found

October 28, 2026•5 min read

Pooling 27 randomized trials, men given testosterone were about twice as likely to have a meaningful drop in depressive symptoms.

This article walks through the JAMA Psychiatry (2019) paper in plain English: what was studied, what changed, what the limits are, and what it does not prove. Full citation and DOI link are at the end, with a PubMed record.

What the study found

This systematic review and meta-analysis pooled 27 randomized, placebo-controlled trials covering 1,890 men, published in JAMA Psychiatry in 2019. It included men across a broad age range, both with and without low testosterone, who reported depressive symptoms on validated scales.

Testosterone was associated with a significant reduction in depressive symptoms (Hedges g 0.21) and a higher chance of a 50% or greater symptom reduction (OR 2.30), with similar dropout to placebo. The effect was small and the trials were heterogeneous, so the authors call for more targeted trials.

Key finding (from the study record): TRT associated with reduced depressive symptoms vs placebo (Hedges g 0.21, 95% CI 0.10-0.32); response odds ratio 2.30 (1.30-4.06); dropout similar.

How the study was done

  • Design: Systematic review and meta-analysis of 27 RCTs
  • Who was studied: 1,890 men
  • Journal / year: JAMA Psychiatry (2019)
  • First author: Walther A et al.

From the abstract: IMPORTANCE: Countering depressive disorders is a public health priority. Currently, antidepressants are the first-line treatment, although they show modest effects. In men, testosterone treatment is a controversial alternative or adjunct treatment option.

What it means — and what it does not

Useful takeaway: Pooling 27 randomized trials, men given testosterone were about twice as likely to have a meaningful drop in depressive symptoms.

Limits and caveats: Small effect size; high heterogeneity; mixed eugonadal/hypogonadal men. Not a substitute for depression care.

This evidence can inform a conversation with a licensed provider. It is not a guarantee of similar results for you, and it is not a recommendation to start, stop, or change any medication on your own.

Related research we cite

How this connects to care

AZTRT serves men in Arizona with telehealth evaluation, labs, and provider-guided plans when appropriate. Plans start at $149/month or $357/quarter and include initial labs only. Medication ships three months at a time when prescribed.

Relevant pages on this site:

FAQ

What did this study actually find?

Pooling 27 randomized trials, men given testosterone were about twice as likely to have a meaningful drop in depressive symptoms. The design was: Systematic review and meta-analysis of 27 RCTs. Population: 1,890 men.

Does this mean I should start treatment?

No. Research informs care; it does not prescribe it. A licensed provider reviews your symptoms, labs, and history before any decision. Results vary.

What are the main limits of this evidence?

Small effect size; high heterogeneity; mixed eugonadal/hypogonadal men. Not a substitute for depression care.

Keep reading

Practical questions to bring to a consult

Research is most useful when it turns into better questions:

  • Do my symptoms and labs line up with the kind of men this study enrolled?
  • Which of the study’s limits apply to me (age, heart risk, anemia, fertility goals, medications)?
  • What monitoring would we use if we tried a related therapy — hematocrit, PSA, glucose, sleep, or something else?
  • Are we talking about a branded FDA-approved medication, a different formulation, or a compounded product that is not FDA-approved?

A short, honest consult is the right place for those answers — not a social post. Book a free consult with an Arizona-licensed provider.

Reference

Walther A et al. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019. https://doi.org/10.1001/jamapsychiatry.2018.2734 · PubMed 30427999.

Next step

Book a free consult with an Arizona-licensed provider. Bring your questions — including anything this study raised for you.

Plans start at $149/month or $357/quarter and include initial labs only. Medication ships three months at a time when prescribed.

Talk to a licensed provider. Results vary. Not medical advice.

Free consult
Book a free consult with an Arizona-licensed provider
Book free consult →

Talk to a licensed provider. Results vary. Not medical advice.

Back to Blog

AZTRT LLC is a management services organization (MSO). AZTRT LLC does not practice medicine, does not provide medical advice, and does not make any medical decisions. All consultations, diagnoses, prescriptions, and treatment decisions are made solely by independent, licensed healthcare providers who are solely responsible for the care they deliver; AZTRT LLC does not own the medical practice and does not control or interfere with the exercise of professional medical judgment. AZTRT LLC provides administrative, business, and technology support services and connects patients with these independent providers and partner pharmacies. AZTRT LLC is not liable for the acts or omissions of any provider or pharmacy. Telemedicine services are available exclusively to residents of Arizona and only when clinically appropriate following a provider consultation and lab review. Prescription products require a valid prescription from a licensed provider. Individual results vary. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease, and are not a substitute for professional medical advice.